Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

134.86 -1.40 (-1.03%)
Delayed Quote Updated: 4:00 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Protagonist Therapeutics (NASDAQ:PTGX) Eyes Breakout as High Growth Momentum Builds ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX): Strong Growth Meets Constructive Technical Setup ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX): High Growth Momentum Meets Breakout Setup ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Combines Strong Growth With a High-Quality Technical Setup ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Combines High Growth Momentum With a Breakout Setup ↗
Via Chartmill
News headline image
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment ↗
Protagonist Therapeutics (NASDAQ:PTGX) said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia... 
Via MarketBeat
News headline image
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗
One of J&J's investments stands head-and-shoulders above the rest. 
Via The Motley Fool
Protagonist Therapeutics (NASDAQ:PTGX) Combines Strong Growth with a Promising Technical Setup ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Screens as an Affordable Growth Opportunity ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Passes Minervini Trend Template and High-Growth Screen ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX): A High Growth Momentum Stock Meeting the Mark Minervini Technical Setup ↗
Via Chartmill
Protagonist Therapeutics (NASDAQ:PTGX) Shows Technical Strength and High Growth Momentum ↗
Via Chartmill
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology. 
Via The Motley Fool
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases. 
Via The Motley Fool
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market
In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of... 
Via MarketMinute
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗
This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance ↗
This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes ↗
The chief medical officer at one of the top pharmaceutical companies sold nearly 10,000 shares in late January 2026, but the reason was for something very simple. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape
As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Protagonist (PTGX) Earnings Call Transcript ↗
Protagonist (PTGX) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
What 7 Analyst Ratings Have To Say About Protagonist Therapeutics ↗
 
Via Benzinga
News headline image
Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million ↗
Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million 
Via The Motley Fool
Topics Energy
News headline image
Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million ↗
Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million 
Via The Motley Fool
News headline image
Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million ↗
Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.